Januvia no longer contraindicated in renal impairment

Januvia (sitagliptin) can now be used at a lower dose in patients with moderate to severe renal impairment.

No dose adjustment is required based on age
No dose adjustment is required based on age

Clinical study

In an open-label study, the pharmacokinetics of Januvia (sitagliptin) were assessed in patients with differing degrees of renal impairment and those with end-stage renal disease on haemodialysis (ESRD). Patients were administered a reduced single dose of 50mg sitagliptin.

A clinically significant increase in plasma concentration of sitagliptin was not observed in patients with mild renal impairment in comparison with normal healthy patients. In contrast, an approximate 2-fold increase in plasma AUC of sitagliptin was seen in patients with moderate renal impairment and an approximate 4-fold increase was observed in patients with severe renal impairment and patients with ESRD on haemodialysis.

Dosage recommendations

No dose adjustment is required in patients with mild renal insufficiency (CrCl ≥50ml/min). For patients with moderate renal impairment (CrCl 30 to 50ml/min), the dose of Januvia is 50mg once daily. In patients with severe renal impairment (CrCl <30ml/min) or end-stage renal disease requiring dialysis, the dose of Januvia is 25mg once daily.

Renal function should be assessed before starting and measured periodically thereafter.

Recommendations do not apply to Janumet

The combination product Janumet (sitagliptin + metformin) is still contraindicated in patients with moderate to severe renal impairment owing to the metformin component.

View Januvia drug record

View Janumet drug record

Further information: Merck Sharp & Dohme Ltd

Updated 27 April 2012

New strengths of Januvia available

Januvia is now available as 25mg and 50mg tablets to facilitate dosing in moderate to severe renal impairment.

 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases